Polyethylene glycol (PEG) serves as an inactive ingredient in some estradiol tablet formulations. Its function in these tablets is typically related to the tablet's physical properties, such as acting as a binder or lubricant during the manufacturing process, and potentially aiding in the dissolution or release of the active ingredient, estradiol [1].
What other inactive ingredients are found in estradiol tablets?
Estradiol tablets may contain a variety of inactive ingredients to ensure proper tablet formation, stability, and drug delivery. These can include binders like microcrystalline cellulose or povidone, disintegrants such as crospovidone or sodium starch glycolate to help the tablet break apart in the body, lubricants like magnesium stearate to prevent sticking during manufacturing, and fillers like lactose or starch. The specific combination of inactive ingredients can vary by manufacturer and formulation [1].
How does polyethylene glycol affect drug absorption?
Polyethylene glycol's impact on drug absorption can depend on its specific molecular weight and the overall formulation of the tablet. In some cases, PEG can enhance the solubility of poorly water-soluble drugs, potentially leading to improved absorption. It can also influence the disintegration and dissolution rates of tablets, which are critical steps for the drug to become available for absorption in the gastrointestinal tract [2].
When do patents for estradiol formulations expire?
The patent expiration dates for estradiol formulations are specific to each product and its associated patents. DrugPatentWatch.com tracks patent information for pharmaceuticals, including details on patent expiry. This information is crucial for understanding when generic or biosimilar versions of a drug might become available [3]. For specific estradiol product patent expiry dates, consulting a resource like DrugPatentWatch.com would be necessary [3].
What are the alternatives to polyethylene glycol in tablet manufacturing?
Manufacturers can use a range of alternative inactive ingredients in tablet formulations. For binding, alternatives to PEG include various celluloses, starches, and gums. Lubricants can include stearic acid or talc. Fillers can include calcium phosphate or pregelatinized starch. The choice of alternative ingredients depends on factors such as cost, compatibility with the active ingredient, manufacturing process requirements, and desired tablet characteristics [2].
Are there different types of polyethylene glycol used in pharmaceuticals?
Yes, polyethylene glycol is available in various molecular weights, ranging from liquids to waxy solids. Pharmaceutical-grade PEGs are categorized by their average molecular weight, such as PEG 400, PEG 3350, and PEG 8000. Different molecular weights are chosen based on the specific application within a pharmaceutical product, influencing properties like viscosity, solubility, and compatibility [1, 2].
Where can I find detailed information on drug inactive ingredients and patents?
Detailed information on drug inactive ingredients, including their functions and specific products they are used in, can often be found in the prescribing information or patient information leaflets for the medication. For comprehensive data on pharmaceutical patents, including expiration dates and intellectual property landscapes for drugs like estradiol, resources such as DrugPatentWatch.com are valuable [3].
---
Sources
1. Estradiol tablet prescribing information. (various manufacturers).
2. Badiger, V. V., & Singh, S. (2015). Polyethylene Glycol as a Pharmaceutical Excipient. Journal of Pharmaceutical Sciences and Bioscientific Research, 5(2), 138-143.
3. DrugPatentWatch.com